The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bone effects of adjuvant tamoxifen (T), letrozole (L), or L plus zoledronic acid (Z) in early breast cancer (EBC): The phase III HOBOE study.
F. Perrone
No relevant relationships to disclose
C. Gallo
No relevant relationships to disclose
S. Lastoria
No relevant relationships to disclose
F. Nuzzo
No relevant relationships to disclose
A. Gravina
No relevant relationships to disclose
G. Landi
No relevant relationships to disclose
E. Rossi
No relevant relationships to disclose
C. Pacilio
No relevant relationships to disclose
V. Labonia
No relevant relationships to disclose
F. Di Rella
No relevant relationships to disclose
M. De Laurentiis
No relevant relationships to disclose
M. C. Piccirillo
No relevant relationships to disclose
M. Di Maio
No relevant relationships to disclose
P. Giordano
No relevant relationships to disclose
G. Daniele
No relevant relationships to disclose
G. De Feo
No relevant relationships to disclose
R. Fiore
No relevant relationships to disclose
S. Signoriello
No relevant relationships to disclose
G. Esposito
No relevant relationships to disclose
A. de Matteis
No relevant relationships to disclose